Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose Escalation of rESP (SSS06) in Healthy Subjects
NCT02356419Phase 1Unknown
- Sponsor
- 3SBio
- Start
- Sep 2014
- Primary completion
- Jan 2015
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of SSS06 in anemia of chronic kidney disease (CKD-A) (4 arms), sponsored by 3SBio. Primary endpoint: Reticulocyte counts at 6 months. Status: unknown.
02
Drugs
SSS06
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT02356419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02356419.